Evidence map›Paper›PMID 41138035›Full record

ArticleScience China. Life sciences2026

The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China.

Feifei Tang, Yunqi Wang, Yu Zhang, Hongyu Zhang, Jinhai Ren, Pengcheng He, Yajing Xu, Hua Yan, Yongqian Jia, Liping Dou and 10 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Feifei Tang *Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, 100044, China.
Yunqi Wang *Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, 100044, China.
Yu ZhangNanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Hongyu ZhangPeking University Shenzhen Hospital, Shenzhen, 518036, China.
Jinhai RenHematology Institute of Hebei Province, Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Pengcheng HeThe First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Yajing XuXiangya Hospital, Central South University, Changsha, 410008, China.
Hua YanRuijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Yongqian JiaWest China Hospital of Sichuan University, Chengdu, 610041, China.
Liping DouChinese PLA General Hospital, Beijing, 100853, China.
Tao WuThe 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, 730050, China.
Zhi GuoHuazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, 518052, China.
Xiaojun YuanXinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Yongjun FangChildren's Hospital of Nanjing Medical University, Nanjing, 210008, China.
Xiaoyan WuUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Qian JiangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, 100044, China.
Hao JiangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, 100044, China.
Lanping XuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, 100044, China.
Xiaohui ZhangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, 100044, China.
Xiaojun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, 100044, China. huangxiaojun@bjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to firstly explore characteristics and prognostic factors of therapy-related acute myeloid leukemia (t-AML) in multi-center samples in China. We analyzed 228 t-AML patients from 14 centers across China. The median age at t-AML diagnosis was 52 years (range, 1.3-89 years). The median latency interval was 45.8 months (19.2-142.8 months). Next generation sequencing (NGS) results were available in 150 (65.8%) patients. The overall survival (OS) and disease-free survival rates of all t-AML were 58.3% and 63.7%, respectively. In t-AML patients, NPM1 mutation (85.0% vs. 54.4%, P=0.01), core binding factor (CBF) (RUNX1/RUNX1T1 and CBFβ/MYH11) (70.7% vs. 55.1%, P=0.03), and allogeneic hematopoietic stem cell transplantation (allo-HSCT) (86.0% vs. 67.9%, P=0.02) were associated with significantly better OS, while the 2022 ELN intermediate-adverse risk group had worse OS than the favorable group (55.9% vs. 73.1%, P=0.02). In multivariable analyses, NPM1 mutation, CBF t-AML, primary tumor remission, WBC count ⩽15×10

Indexed as

Leukemia, Myeloid, AcuteAdolescentAdultAgedAged, 80 and overChildChild, PreschoolChinaDisease-Free SurvivalFemaleHematopoietic Stem Cell TransplantationHigh-Throughput Nucleotide SequencingHumansInfantMaleMiddle AgedNPM1 protein, humanNuclear ProteinsNucleophosminnext generation sequencingprognostic analysistherapy-related acute myeloid leukemia

Identifiers

PMID41138035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.